Introduction {#Sec1}
============

Cellular circular RNAs (circRNAs) represent a class of single-stranded, unusually stable RNAs originating from 5′-to-3′ transcription of coding gene exons or long non-coding RNAs (lncRNAs) that produce covalently closed head-to-tail (or back-spliced) circularized transcripts \[[@CR1]--[@CR4]\]. Many circRNAs are tissue- and developmental stage-specifically expressed \[[@CR2], [@CR4]\]. The circRNA co-transcriptional splicing can compete with linear splicing events and can depend on the binding of the RNA-binding proteins, MBNL1 or QKI, in intronic sequences \[[@CR5], [@CR6]\]. Intronic complementary sequences, inter alia repetitive elements, and the RNA-editing protein, ADAR1, were linked to the circularization of exons \[[@CR7], [@CR8]\]. Earlier, the circRNAs CDR1as (ciRS-7) and circSRY were shown to exhibit important functions in sponging miRNAs and thereby functioning as post-transcriptional regulators \[[@CR2], [@CR9], [@CR10]\]. circRNAs are resistant to the exonuclease RNase R that solely digests linear transcripts. This feature can be used to validate circRNA candidates by comparing their abundance in the RNase R-treated and untreated samples \[[@CR11]\]. circRNAs found in clinical specimens, like blood, reveal that these abundant transcripts could serve as biomarkers \[[@CR12]\]. Here, we present a circRNA resource catalog to supplement existing databases with new circRNA transcripts in human cell types. By identifying and validating selected circRNAs in these human tissues relevant to clinical research, we provide multiple examples of abundant and highly tissue-specific circRNA expression in host genes that have been associated with pathogenesis of human disease.

Methods {#Sec2}
=======

Human material {#Sec3}
--------------

After approval by the ethics committee (Charité Medical Faculty Berlin and University Clinic Erlangen) and written, informed consent, we obtained human tissues. Mesenchymal stromal cells (MSCs) from a non-affected healthy female (23 years) donor were obtained, characterized, and differentiated as previously described \[[@CR13]\]. Fibroblasts from buttocks biopsies of a non-affected male donor (25 years) were cultivated until passage six in M-199, supplemented with 20% FCS. Single samples, each from one donor, were used for sequencing.

Patients or patients' parents signed informed consent on anonymous data collection for research studies conducted on biological samples of patients with primary immunodeficiencies (three Wiskott-Aldrich syndrome samples, four ADA-SCID samples) at San Raffaele Hospital (TIGET02), approved by the San Raffaele Scientific Institute's Ethical Committee. Four T cell lines were generated from peripheral blood mononuclear cells purified by density gradient centrifugation on Ficoll-Hypaque (Nycomed Pharma, Oslo, Norway) and expanded \[[@CR14]\].

Tissue preparation {#Sec4}
------------------

Adipose tissue was extracted during lipo-aspiration of MSCs from upper abdominal fat. The tissue was rinsed with PBS on Teflon fleece to wash out erythrocytes. Fat spheres were subsequently frozen in liquid nitrogen. Neutrophils were extracted from peripheral whole blood that was supplemented with 30% of dextran. Cells settled down in a syringe after 30 min. The upper phase was under-laid with histopaque 1083. After centrifugation at 4 °C for 30 min at 1200 rpm, speed was slowed down to 1050 rpm after 15 min for another 15 min. Pelleted cells were resuspended in 10 ml water for water lysis. For neutralization, 3.33 ml of 3.6% NaCl was added for 10 min. After 10 min centrifugation at 1050 rpm, pelleted neutrophils were resuspended in TRIzol® Reagent (Ambion). Plasma, serum, and platelets were prepared using the Vacutainer system. Whole blood in serum tubes was left undisturbed for clot formation. After 15--30 min, the clot was centrifuged at 1000×*g* for 10 min and the supernatant serum was immediately frozen at −80 °C. Plasma was prepared from whole blood in EDTA tubes. After a centrifugation at 2000×*g* for 10 min, the supernatant was frozen. Citrate tubes were used to obtain platelets. The whole blood was centrifuged for 15 min at 100×*g* without rotor break, preventing platelets' activation. Endothelial progenitor cells (EPCs) were extracted from umbilical cord blood and expanded in vitro using the Lonza EGM™-2 kit. Human umbilical vein cells (HUVECs) were freshly prepared using standard techniques from umbilical cord and cultivated until passage four in EGM medium (Lonza). Adipose tissue, cortex, placenta, decidua, heart, vena cava, muscle, and umbilical cord were minced using pistils and homogenized with matrix beads in the MP FastPrep-24 Tissue and Cell Homogenizer.

RNA preparation for RNA-seq and qRT-PCR analysis of selected circRNA candidates {#Sec5}
-------------------------------------------------------------------------------

RNA was prepared using TRIzol® Reagent (Ambion) and phenol/chloroform precipitation. For Illumina sequencing, rRNA depletion was done with the RiboMinus™ eukaryote kit according to manufacturer's recommendation (Life Technologies). Bioanalyzer measurement validated the successful rRNA depletion. The Illumina TruSeq sample preparation kit (v2) was used to generate the libraries for sequencing. For qRT-PCR, total RNA of the identical samples that were used for RNA-seq was digested with RNase R (3 U/μg RNA, Epicenter Technologies) and incubated for 15 min at 37 °C with following inactivation for 3 min at 95 °C. To reach similarly effective RNase R treatment, all samples were treated simultaneously in one approach. Then, the RNA was spiked with 10% of *Caenorhabditis elegans* total RNA. After phenol/chloroform precipitation, the RNA was reverse transcribed using RevertAid first strand cDNA synthesis kit (Fermentas) or Maxima RT kit (ThermoFisher Scientific), and SYBR-green quantification (Roche) was performed according to standard protocols on ABI 7500 or StepOnePlus (ThermoScientific). Oligonucleotides flanking the circRNA head-to-tail junctions were designed in Primer3 (v. 0.4.0). RNase R assays were normalized to *C. elegans eif3d* spiked-in RNA and to human *GAPDH* or *Vinculin*. For experiments on WAS and ADA-SCID samples, ΔCt was calculated compared to 28S rRNA. In general, expression was quantified applying the ΔΔCt method. qRT-PCR products were analyzed for amplicon size, specificity, and integrity on 3% agarose gels; concatemers were not taken into account. Sanger sequencing of qRT-PCR products was performed using the Big Dye® Terminator Cycle Sequencing on the 3130xl Genetic Analyzer (ABI) using Gene Mapper® Software Version 4.0. Kit v1.1 (ABI). SeqMan software (Lasergene Version 7.0; DNAStar) was used to analyze the traces.

circRNA detection and annotation {#Sec6}
--------------------------------

circRNAs were detected and annotated using the Memczak et al. (2013) pipeline. Human genome reference used for all analyses was hg19 (February 2009, GRCh37), downloaded from UCSC \[[@CR15]\]. Upon detection, candidates were annotated using RefSeq and GENCODE v17 gene models. Table S[2](#MOESM3){ref-type="media"} and circBase summarize the detected circRNAs across all cell types. Table S[2](#MOESM3){ref-type="media"} harbors genomic positions and annotated host transcripts, sense or antisense strand orientation, circBase IDs, genomic and spliced lengths, number of sequencing reads supporting a head-to-tail junction, as well as the number of either 5′ or 3′ linear reads for each circRNA candidate. We also calculated the circular-to-linear ratios and added the list of samples from other studies listed within circBase.

Data availability {#Sec7}
-----------------

RNA sequencing data have been deposited in the Gene Expression Omnibus (GEO) under the accession number GSE100242.

circRNA quantification {#Sec8}
----------------------

The ratio of circular and linear isoforms (circular-to-linear ratio, CLR) was calculated as described in \[[@CR16]\]. For each circRNA candidate, we counted the number of reads overlapping the head-to-tail junction, and the number of reads spliced linearly over the 5′ and 3′ sites that gave rise to a circRNA. CLR was expressed as the number of reads spanning the head-to-tail junction divided by the number of linear reads mapped over the splice site (5′ or 3′) with the higher read count:$$\documentclass[12pt]{minimal}
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To avoid division by zero when calculating CLR, a pseudocount of 1 was used where no linearly spliced reads were detected. To estimate the expression levels of circRNA host genes, we mapped RNA-seq libraries to the hg19 reference using STAR \[[@CR17]\] and counted the reads mapped to Ensembl (release 75) gene models using the htseq-count tool \[[@CR18], [@CR19]\].

circRNA expression heatmaps {#Sec9}
---------------------------

circRNAs in Figs. [1c](#Fig1){ref-type="fig"} and [2a, c](#Fig2){ref-type="fig"} were sorted into three discrete expression classes: (i) "high"---top 10% (5% for platelets) expressed, measured by raw read counts, circRNAs in a particular sample; (ii) "detected"---all circRNAs that satisfied the minimum expression threshold of two unique reads overlapping head-to-tail junction; and (iii) "not detected"---circRNAs that were not detected in a particular sample. Only circRNAs that were assigned to "high" category in at least one of the compared samples were plotted.Fig. 1CircRNA expression in clinically relevant human tissues. **a** CircRNA catalog of human samples with total, new, and unique circRNAs. Samples in bold were derived from one donor. **b** Distribution of host gene annotation with potential circRNAs. **c** Differentially expressed top 10% circRNAs in hierarchical clustering. **d** CircRNAs from different clusters (C) were validated by qRT-PCR of RNase R-treated samples Fig. 2CircRNAs are tissue-specific, highly abundant, and the expression can be differential in disease-associated genes. **a** Clustering of top 10% differentially expressed circRNAs in umbilical cord, EPCs, HUVECs, and HUAECs and **b** their validation. **c** Tissue-specific expression pattern reflected the overlaps of circRNAs in plasma, serum, neutrophils, and platelets and **d** their validation. **e** Circular-to-linear expression ratios revealed highly expressed circRNAs with multiple isoforms. **f** Validation of circRNAs from disease-relevant genes (*GAPDH; Vinculin*---linear negative control; *hsa-circRNA-5*---positive control). **g** CircRNA quantification in three different WAS and four ADA-SCID patients (AFF). The candidates were higher expressed in disease samples than in four controls (bars: mean expression ± SEM, two technical replicates per WAS or ADA-SCID patient group, except *circCDC42BPA*: controls *n* = 6, WAS *n* = 5, Student's *T* test across samples and replicates, \*\*\**p* \< 0.001, \*\**p* \< 0.01, \**p* \< 0.05)

Differential gene expression {#Sec10}
----------------------------

Differential gene expression analysis was performed using the DESeq package \[[@CR20]\]. method="blind" and sharingMode="fit-only" options were used when running the estimateDispersions function, as suggested by the package documentation for experimental designs with no biological replicates.

In-solution protein digest {#Sec11}
--------------------------

Peptides were generated using an automated setup \[[@CR21]\]. Briefly, samples were reduced with 1 mM tris(2-carboxyethyl) phosphine (TCEP) and free sulfhydryl groups carbamidomethylated using 5.5 mM chloroacetamide. Proteins were pre-digested with 0.5 μg sequencing grade endopeptidase LysC (Wako) for 3 h at room temperature and subsequently diluted with four volumes of 50 mM ammonium-bicarbonate (ABC). Tryptic digestion occurred for 10 h at room temperature using 1 μg sequencing grade trypsin (Promega). The reaction was stopped by adding trifluoroacetic acid (TFA) to a final concentration of 1% resulting in a final pH of 2. The peptides were purified by using C~18~ stage-tips (3 M) \[[@CR22]\].

Mass spectrometry {#Sec12}
-----------------

Peptides eluted from C~18~ stage-tips were run on an LC-MS setup. The fractionated and unfractionated samples were measured by LC-MS/MS on a Q Exactive orbitrap mass spectrometer (Thermo) connected to a Proxeon nano-LC system (Thermo) in data-dependent acquisition mode using the top 10 peaks for HCD fragmentation. Peptides were separated on an in-house prepared nano-LC column (0.074 mm × 250 mm, 3 μm Reprosil C~18~, Dr. Maisch GmbH). Five microlitres of the sample were injected and the peptides were eluted on a 3-h gradient of 4 to 76% ACN and 0.1% FA in water at flow rates of 0.25 μl/min. MS acquisition was performed at a resolution of 70,000 in the scan range from 300 to 1700 *m*/*z*, MS2 spectra were collected at a mass resolution of 17,000 with a fixed injection time of 120 ms. Dynamic exclusion was set to 30 s and the normalized collision energy was specified to 26. The eluent was directly sprayed into an Q Exactive mass spectrometer (Thermo Fisher Scientific) equipped with a nano electrospray ion source. The recorded spectra were analyzed using MaxQuant software package version 1.5.2.4 \[[@CR23]\], with an Andromeda search using the combined UniProt *Homo sapiens* and *Oryctolagus cuniculus* databases and a custom database for the circRNA-derived peptides with a false discovery rate of 1% (peptides and proteins). The fixed and variable modifications were set to carbamidomethylation of cysteines and methionine oxidation, respectively. For further data analysis, the R statistical software package was used ([supplement](#MOESM1){ref-type="media"}: python script).

Results {#Sec13}
=======

circRNA resource catalog of 20 human tissues {#Sec14}
--------------------------------------------

We generated a circRNA resource catalog for various research interests by sequencing ribosomal RNA-depleted total RNA (Supplemental Table S[1](#MOESM2){ref-type="media"}). The head-to-tail splice junction identification and the sequence analysis were done according to previously published protocols (Supplemental Fig. S[1](#MOESM2){ref-type="media"}), \[[@CR2], [@CR24]\]. The circRNA catalog can be retrieved in Supplemental Table S[2](#MOESM3){ref-type="media"} or circBase, <http://www.circbase.org/> \[[@CR24]\]. We selected circRNA candidates for validation according to either of the following criteria: (i) the candidate originated from disease or developmental genes (Table [1](#Tab1){ref-type="table"}); (ii) the linear host transcripts have been proposed as biomarkers; (iii) the circRNA was not present in circBase; (iv) the circRNA was encoded from a lncRNA; or (v) the circRNA showed extraordinary genomic length or expression determined via the read count. In total, we selected 112 candidates, of which we validated 71 circRNAs by RNase R assays (validation rate 63.4%, see "[Methods](#Sec2){ref-type="sec"}", Supplemental Fig. S[2](#MOESM2){ref-type="media"}a--p). We normalized expression values to *C. elegans eif3d* spiked-in RNA and to human *GAPDH* or *Vinculin*. Concatamers in putative circRNA candidates were not taken into account.Table 1Validated circRNAs of known disease-associated genescircRNADiseaseTissueCircular reads5′ linear reads3′ linear readsCLRReference for mRNA*circPLOD2*Osteoarthritis-related synovial fibrosisOsteocytes2550.4\[[@CR25]\]*circEFEMP1*Ovarian cancer, glioblastomaHUVEC229160.1\[[@CR26]\]*circNTRK2*Huntington's diseaseCortex431960\[[@CR27]--[@CR29]\]*circRTN4*Alzheimer's diseaseCortex2104470\[[@CR30]\]*circHOMER1*Traumatic neuronal injury, mental retardation, Alzheimer's disease, schizophrenia, drug addictionCortex91080.9\[[@CR31], [@CR32]\]*circATXN10*Spinocerebellar ataxia type 10Cortex318210.1\[[@CR33]\]*circPSG5*Pregnancy complicationsPlacenta222600.8\[[@CR34]\]*circPAPPA2*Preeclampsia, fetal growth restriction, HELLP syndromePlacenta62131720\[[@CR35]--[@CR38]\]*circALPPTrypanosoma cruzi* infection during pregnancyPlacenta272900.9\[[@CR39]\]*circNPPA*Type 2 diabetes, cardiovascular disordersHeart9269500\[[@CR40], [@CR41]\]*circCORIN*Heart failureHeart, vena cava213290\[[@CR42]\]*circRYR2*Atrial fibrillationHeart, vena cava256590\[[@CR43]\]*circMYH6*Hypertrophic cardiomyopathiesHeart23642040\[[@CR44]\]*circSLC8A1*Cardiovascular disordersHeart3716510.7\[[@CR45]\]*circPDE3A*HypertensionPlatelets5360.8\[[@CR46], [@CR47]\]*CLR* circular-to-linear ratio

Of the 5225 circRNAs, 35.9% (1878 circRNAs) were new compared to circBase \[[@CR24]\]. circRNAs (3841) were unique for the investigated cell types (Fig. [1](#Fig1){ref-type="fig"}a). We detected 82.9% circRNAs in coding genes (exons, 5′ + 3′ UTRs), 2.2% antisense transcripts, 5.4% intron-derived circRNAs, 6% in non-coding genes, and 1.1% from intergenic regions (Fig. [1](#Fig1){ref-type="fig"}b).

circRNA expression in mesenchymal stem cells and MSC-derived cells {#Sec15}
------------------------------------------------------------------

First, we analyzed circRNA expression during MSC differentiation. MSCs were differentiated into proliferating chondrocytes, osteocytes, and vascular smooth muscle cells (VSMCs). Flow cytometry revealed CD105^+^, CD90^+^, CD73^+^, HLA-ABC^+^, CD31^−^, CD34^−^, CD45^−^, and HLA-DR^−^ cells and the multi-lineage potential validated MSC properties \[[@CR46], [@CR48]\]. In MSCs, we detected 55 circRNAs, in contrast to 148 in MSC-derived chondrocytes, 104 in osteocytes, or 137 in VSMCs. In chondrocytes, we validated a circRNA deriving from *PLOD2*, a gene which forms collagen crosslinks and was differentially expressed in a model of osteoarthritis-related synovial fibrosis \[[@CR25]\]. During the abdominal fat aspiration to obtain MSCs, we additionally harvested adipose tissue that harbors the MSC niches \[[@CR49]\]. In the abdominal fat of the same MSC donor, we identified 507 circRNAs. We confirmed a circRNA in *SORBS1*, a gene inhibiting the induction of glucose transport by insulin, and two circRNAs in *PLIN4*, a gene stimulating lipolysis in adipocytes (Supplemental Fig. S[2](#MOESM2){ref-type="media"}a--d) \[[@CR50], [@CR51]\]. When comparing different MSC-derived tissues, we commonly observed different circRNA isoforms spliced from the same host genes in different MSC-derived cells. Solely eight circRNAs overlapped between adipose tissue, MSCs, and their derived cells (Supplemental Table S[2](#MOESM3){ref-type="media"}). In eight different tissues of one healthy donor, we excluded interindividual differences and found tissue-restricted expression patterns (Fig. [1](#Fig1){ref-type="fig"}a). The absence of circRNA housekeeper and direct comparisons of circRNA expressions between different tissues are controversially discussed endeavors. Thus, we selected the top 10% circRNA candidates within MSCs and MSC-derived cells and clustered 31 circRNAs candidates based on their expression levels: "not detected," "detected" with at least two reads, or "highly expressed" when detected within the top 10% of the candidates (Fig. [1](#Fig1){ref-type="fig"}c). We observed ubiquitous expression for some circRNAs and differential expression regarding the MSC-derived cells. We validated selected circRNA candidates within the cluster analysis showing RNase R resistance and confirmed the results of clustering (Fig. [1](#Fig1){ref-type="fig"}d and Supplemental Fig. [2](#MOESM2){ref-type="media"}q).

circRNAs in disease-associated genes of clinically relevant tissues {#Sec16}
-------------------------------------------------------------------

Next, we compared physiologically neighboring tissues: umbilical cord, endothelial progenitor cells (EPCs), HUVECs, and HUAECs. Of the 211 circRNAs in HUAECs, only two overlapped with the other tissues. *EFEMP1*, an angiogenesis promoter, poor prognostic marker in ovarian cancer, and potential therapeutic target in glioblastoma treatment, harbored a circRNA in HUVECs (22 circRNAs) \[[@CR26], [@CR52]\]. As previously described, we analyzed the top 10% of the circRNA candidates. A pool of 43 circRNAs showed differential expression and we validated two circRNAs (Fig. [2](#Fig2){ref-type="fig"}a, b and Supplemental Fig. [2](#MOESM2){ref-type="media"}q).

In cerebral cortex (339 circRNAs), we validated circRNAs spliced from important cerebral genes. *ERC2* is involved in neurotransmitter release and expresses a circRNA \[[@CR53]\]. Five circRNA isoforms were found in *ATRNL1*, a gene regulating the energy homeostasis by melanocortins in the hippocampus \[[@CR54]\]. Another circRNA is hosted by *NTRK2*, a gene that was associated with synaptic dysfunction in Huntington's disease and neuronal differentiation and plasticity in hippocampus \[[@CR27]--[@CR29]\]. We validated a circRNA in *RTN4*, a gene inhibiting axonal sprouting and modulating Alzheimer's disease progression in a mouse model and one of two predicted circRNAs in *HOMER1*, a gene that is involved in synaptic activity and various neurological disorders \[[@CR30]--[@CR32]\]. Three circRNAs were expressed in *ATXN10* that maintains the survival of neurons, studied in the spinocerebellar ataxia type 10 (Supplemental Fig. S[2](#MOESM2){ref-type="media"}g) \[[@CR33]\].

In placenta, we detected 63 circRNAs, in comparison to 173 in decidua; 15 circRNAs overlapped. We confirmed a circRNA in *PSG5*, a gene encoding a pregnancy-specific glycoprotein. Low levels indicate pregnancy complications \[[@CR34]\]. Severe early onset preeclampsia, fetal growth restriction, and HELLP syndrome were associated with high expression of *PAPPA2* that encoded two circRNAs \[[@CR35]--[@CR38]\]. *ALPP*, less expressed and active in hyperglycemic and diabetic placentas of pregnant women infected with or without *Trypanosoma cruzi*, harbored a circRNA (Supplemental Fig. S[2](#MOESM2){ref-type="media"}h) \[[@CR39]\].

We also obtained right atrial tissue and vena cava from two children with multiple cardiac defects. Atrium (340 circRNAs) and vena cava (702) had an intersection of 115 circRNAs; 51 overlapped with calf muscle. In atrium, we validated a circRNA in *NPPA*, a gene that was associated with development of type 2 diabetes \[[@CR40]\]. *NPPA* is reactivated in response to cardiovascular disorders and converted to its active form by *CORIN*, which harbored four circRNAs (validated in atrium and vena cava) and could be potential biomarkers for heart failure \[[@CR41], [@CR42]\]. Atrial fibrillation was linked to the dysfunction of *RYR2*, which also produces seven circRNA isoforms in atrium and ten in vena cava \[[@CR43]\]. Mutations in myosin heavy chains cause hypertrophic cardiomyopathies \[[@CR44]\]. In myosin *MYH6*, we validated one circRNA. *QKI* is involved in circRNA biogenesis \[[@CR6]\], is responsible for cardiovascular development, and encodes two circRNAs in atrium and vena cava \[[@CR55]\]. Alterations in the regulation and expression of *SLC8A1* (two circRNAs in atrium) contribute to various cardiovascular symptoms (Supplemental Fig. S[2](#MOESM2){ref-type="media"}i--k) \[[@CR45]\].

circRNAs and their isoforms in platelets {#Sec17}
----------------------------------------

Platelets expressed 3324 circRNAs. Platelets derive from bone marrow megakaryocytes, lack nuclei and highly abundant mRNA reservoirs, although translational capabilities are intact \[[@CR56]--[@CR59]\]. Previously, high circRNA expression and circRNA properties were described in platelets and this enrichment was associated with transcriptome degradation \[[@CR60]\]. We found in our data that platelets harbored much more abundantly expressed circRNAs than any other tissue. For example, circRNA expression in *ACVR2A* and *SMARCA5* was extremely high compared to mRNA (Supplemental Fig. S[3](#MOESM2){ref-type="media"}). We validated circRNAs in the phosphodiesterases *PDE3A*, *PDE4D*, and *PDE5A*. PDEs hydrolyze cAMP and cGMP to control blood vessel relaxation, cardiac contractility, and inhibition of platelet aggregation \[[@CR61]--[@CR64]\]. *PDE3A* was previously associated with Mendelian hypertension \[[@CR46], [@CR65]\]. Moreover, the guanylate cyclase *GUCY1B3* converting GTP into cGMP expressed a circRNA (Supplemental Fig. [2](#MOESM2){ref-type="media"}l--o) \[[@CR66]\].

CircRNA expression in plasma (57), serum (39), suggested that circRNAs could be secreted, as it was shown earlier for micro- and other RNAs, and indicated by circRNAs identified in cell culture or serum exosomes \[[@CR67]--[@CR71]\].

In neutrophils (274 circRNAs), *TLR6* functions in the innate immune response and harbored a circRNA \[[@CR72]\]. Another key component in the immune system expressing a circRNA in neutrophils is *MYO1F*, a class I myosin regulating the host defense against infection \[[@CR73]\]. No overlap between plasma, serum, neutrophils, and platelets facilitates the idea of tissue-restricted circRNA expression. For clustering, we used all plasma and serum circRNAs, the top 10% of neutrophils and the top 5% of platelets and validated four candidates (Fig. [2c, d](#Fig2){ref-type="fig"} and Supplemental Fig. [2](#MOESM2){ref-type="media"}q).

Due to the lack of nuclei and the highly abundant circRNAs in platelets, we hypothesized that circRNAs could serve as templates for translation as recently shown for few circRNA examples in human and fly \[[@CR74], [@CR75]\]. Thus, we used RNase R-treated whole platelet RNA to perform in vitro translation experiments followed by highly sensitive mass spectrometry. We derived putative open reading frames (ORF) that span head-to-tail junctions of our circRNA candidates. These predictions were compared to mass-spectrometrically detected peptides. Controls were reticulocyte lysate of the in vitro translation kit, non-RNase R-treated whole platelet RNA, and total protein of the same platelet-donor. Although we detected peptides in the RNase R-treated translated sample and in the cell lysate matching circRNAs in platelets, those candidates did not overlap with head-to-tail junctions (Supplemental Table S[3](#MOESM4){ref-type="media"}).

We also investigated circRNA isoforms, since we observed around 100 genes hosting more than five different circRNA isoforms. For example, we detected 18 circRNA isoforms derived either from *PTPN12* or *TTN* in platelets, atrium, and vena cava (Supplemental Fig. S[4](#MOESM2){ref-type="media"}). We compared circRNA expression directly to linear transcript expression, by counting linearly spliced and head-to-tail spliced reads. The number of reads overlapping with the head-to-tail splice junctions was divided by the number of linear splicing events with identical splice sites (Supplemental Table S[2](#MOESM3){ref-type="media"}). The calculated value was plotted against the transcript copies per million transcripts (TPM) to describe circRNA expression as circular-to-linear ratio (Fig. [2](#Fig2){ref-type="fig"}e). Collectively, we detected high circular-to-linear expression ratios in tissues with abundant circRNA expression, e.g., a platelet circRNA in *SMARCA5* had a circular-to-linear ratio of 151:1 (Supplemental Fig. S[3](#MOESM2){ref-type="media"}b).

circRNAs are differentially expressed in disease-relevant genes {#Sec18}
---------------------------------------------------------------

Finally, we demonstrate differential circRNA expression in ADA-SCID and WAS, two primary immunodeficiencies which are caused by mutations in *ADA* or *WAS*, respectively \[[@CR76]--[@CR78]\]. First, we compared linear transcripts from one patient compared to a non-affected control. We detected significantly differential expression (*p* ≤ 0.05) of 79 mRNAs in ADA-SCID and 19 mRNAs in WAS lymphoblastoid cells (LCLs) (Supplemental Table S[4](#MOESM5){ref-type="media"} and Supplemental Fig. S[5](#MOESM2){ref-type="media"}a, b). The results were consistent with the molecular pathogenesis of both disease phenotypes. For example, upregulated *BANK1* (*p* = 2.30 × 10^−3^, log2-fold change (lfc) = 3.8) or *PBXIP1* (*p* = 3.53 × 10^−2^, lfc = 2.4) mRNAs in ADA-SCID were associated with impaired B cell receptor-induced calcium mobilization or early blocking of B cell development in the bone marrow (Supplemental Table S[4](#MOESM5){ref-type="media"}) \[[@CR79], [@CR80]\].

We next asked whether these differentially expressed linear transcripts harbor also circRNAs with differential expression between patients and controls. We found a circRNA in *ROBO1*, a gene upregulated in ADA-SCID (mRNA: *p* = 9.76 × 10^−6^, lfc = 5.3) and WAS (mRNA: *p* = 3.68 × 10^−4^, lfc = 8.31, Supplemental Table S[4](#MOESM5){ref-type="media"}). Moreover, *CDC42BPA* expressed an upregulated circRNA in ADA-SCID (mRNA: *p* = 3.46 × 10^−3^, lfc = 4.7) and WAS (mRNA: *p* = 1.93 × 10^−3^, lfc = 7.4). Notably, ROBO1 and CDC42 are linked to the pathogenesis of WAS. Slit-2 and Robo-1 complexes have been described to inhibit the CXCR4/CXCL12-mediated chemotaxis of T cells \[[@CR81]\]. Moreover, ROBO1 and ROBO4 bind WAS to induce filopodia formation \[[@CR82], [@CR83]\]. Cdc42-dependent WAS activation was also reported \[[@CR84], [@CR85]\]. CDC42 is a major regulator of podosome formation and remodels actin during B cell signaling \[[@CR86], [@CR87]\], whereas *CDC42BPA* is a downstream effector of CDC42 \[[@CR88]\]. B cell signaling is impaired both in ADA-SCID \[[@CR79], [@CR80]\] and WAS \[[@CR89], [@CR90]\]. In ADA-SCID, we found a circRNA in *TNFRSF11A* (mRNA: *p* = 8.28 × 10^−3^, lfc = 3.3) TNF receptors participate in several pathways altered in ADA-SCID \[[@CR14]\]. We first validated the circRNAs in *ROBO1*, *CDC42BPA*, and *TNFRSF11A* (Fig. [2](#Fig2){ref-type="fig"}f and Supplemental S[6](#MOESM2){ref-type="media"}a) and tested next their differential expression in three WAS and four ADA-SCID samples, compared to four non-affected LCL samples (Fig. [2](#Fig2){ref-type="fig"}g). circRNA expression of phenotypically relevant genes was higher in the disease samples (Fig. [2g](#Fig2){ref-type="fig"}).

Discussion {#Sec19}
==========

Collectively, we provide a circRNA catalog of human tissues relevant to various fields of clinical research. We provide evidence that circRNAs could serve as biomarkers and that circRNA expression profiles could be directly linked to clinically apparent phenotypes. We focused on detecting circRNAs in various single samples. For further analyzing the proposed circRNA candidates as suitable biomarkers, broader studies addressing tissue specificity vs. donor specificity are needed. Our data corroborate recent findings that circRNA expression is highly tissue-specific \[[@CR2], [@CR16], [@CR91]\]. We did not find evidence that platelet circRNAs were translated; however, our result does not provide conclusive evidence that circRNAs are not translated, as it highly depends on mass-spec sensitivity. As previously suggested \[[@CR60]\], a resistance to RNA degradation can explain the high abundance of circRNAs in platelets. In the absence of transcription, the detected circRNAs could function independently of transcriptional regulation.

As discussed previously \[[@CR2]\], circRNAs uncovered in this study could contribute to regulatory networks governing coding gene expression by acting as miRNA target decoys, RNA-binding protein (RBP) sponges, scaffolding molecules, and transcriptional regulators. A circRNA function is further supported by the conserved nature of circRNA expression and the tissue-specific and regulated abundance \[[@CR16]\]. Although we can only speculate that currently disclosed circRNAs influence the functions of their linear counterparts, these new isoforms need to be considered when investigating disease-relevant genes. Since circRNA biogenesis can compete with pre-mRNA splicing, this opens up the possibility that the mRNA output from those, oftentimes well studied genes, is controlled by the hitherto unknown circRNA \[[@CR5]\].
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